Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) recently saw a significant transaction involving its Executive Vice President and General Counsel, James Basta. On March 4, 2025, Basta sold 2,572 shares of common stock at a price of $8.99 per share, totaling $23,122. This sale was part of a mandatory "sell-to-cover" transaction to satisfy tax obligations related to the vesting of restricted stock units (RSUs) on March 1, 2025, and was not a discretionary trade by Basta. The transaction occurs as NTLA shares trade near their 52-week low of $8.96, having declined over 70% in the past year. InvestingPro analysis indicates the stock is currently undervalued based on its Fair Value assessment.
In addition to the sale, Basta acquired 40,000 shares of common stock on March 1, 2025, through a grant of restricted stock units, at no cost. Furthermore, he received stock options for 57,143 shares with an exercise price of $10.09, which will vest over the next three years. Following these transactions, Basta’s direct ownership stands at 111,925 shares of Intellia common stock, representing a notable stake in the company, which currently has a market capitalization of approximately $941 million. For deeper insights into insider trading patterns and comprehensive financial analysis, including 12 additional ProTips, check out the full research report available on InvestingPro.
In other recent news, Intellia Therapeutics reported better-than-expected fourth-quarter results, with adjusted earnings per share of -$1.27, surpassing analyst estimates of -$1.34. The company’s revenue reached $12.87 million, exceeding the consensus forecast of $9.28 million and marking a significant increase from -$1.9 million in the same quarter last year. Intellia’s current cash balance of $861.7 million is projected to support operations into the first half of 2027. The company has made progress in its clinical pipeline, particularly with NTLA-2002 for hereditary angioedema (HAE), where the first patient was dosed in the global Phase 3 HAELO study.
Meanwhile, several analyst firms have revised their outlooks on Intellia. Truist Securities maintained a Buy rating but reduced its price target from $90 to $50, citing competition concerns and a moderated commercial outlook for its ATTR amyloidosis treatment. Goldman Sachs downgraded Intellia from Neutral to Sell, setting a price target of $9, due to doubts about the differentiation of Intellia’s treatments in a competitive market. JPMorgan also downgraded the stock, cutting the price target to $13 from $45, reflecting a cautious stance. Conversely, Citi raised its price target to $14 from $12 while maintaining a Neutral rating, acknowledging Intellia’s commitment to clinical stage execution.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.